Challenges and benefits in harnessing platform processes for viral vector manufacture
DHC Senior Principal and Head of Gene Tx CMC Scott Cross, M.S., Senior Consultant Christina Fuentes, Ph.D., and Principal Jacob Staudhammer were interviewed through Insights Bio's Cell & Gene Therapy Insights in the following publication which came out on April 23, 2024.
As the demand for AAV and lentiviral vector-driven gene therapies continues to grow, the manufacturing space must overcome manufacturing challenges including issues of cost, scalability, and consistency. David McCall, Senior Editor, BioInsights, spoke with Dark Horse Consulting Group’s Scott Cross, Christina Fuentes, and Jacob Staudhammer (pictured left to right) about the current utility and future potential of platform technologies and processes for viral vector manufacturing.
Continue reading here.
Cell & Gene Therapy Insights 2024; 10(3), 339–344
DOI: 10.18609/cgti.2024.049
